Omniscan

Active Ingredient:: Gadodiamide
Origin:: EU

Omniscan (Gadodiamide)

Q: What is Omniscan used for?

Omniscan is a gadolinium‑based contrast agent used during magnetic resonance imaging (MRI) to improve the visibility of blood vessels, organs and lesions. It helps radiologists obtain clearer images of the brain, heart, abdomen and other body regions, supporting more accurate diagnosis.

Q: How does gadodiamide work as a contrast agent?

Gadodiamide contains a chelated gadolinium ion that is highly paramagnetic. After intravenous injection it distributes in the extracellular fluid and shortens the T1 relaxation time of nearby water protons, producing a brighter signal on T1‑weighted MRI sequences and enhancing the contrast between normal and abnormal tissues.

Q: What is the usual dose of Omniscan?

The dose of Omniscan is determined by the prescribing physician based on the patient’s weight, the imaging protocol and the specific diagnostic requirement. The healthcare professional calculates the appropriate volume and concentration for each individual examination.

Q: Is Omniscan safe during pregnancy or breastfeeding?

Use of Omniscan during pregnancy or lactation should only be considered when the diagnostic benefit outweighs potential risk. Gadolinium agents cross the placenta and may be excreted in breast milk, so clinicians evaluate each case carefully and follow local regulatory guidance.

Q: How do I order Omniscan from GNH India?

To order Omniscan, submit an enquiry on the product page at gnhindia.com indicating the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Q: How does Omniscan compare with other MRI contrast agents?

Omniscan is a non‑ionic, linear gadolinium chelate offering high relaxivity and good image enhancement. Compared with macrocyclic agents, it has a similar efficacy for most MRI studies but may carry a slightly higher risk of nephrogenic systemic fibrosis in patients with severe renal impairment, prompting careful patient selection.

Q: What are the storage and handling requirements for Omniscan?

Omniscan should be stored at ambient temperature, below 25 °C, protected from light and kept in its original packaging. Do not freeze the product. Before administration, inspect the vial for particulate matter and ensure the solution is clear.

Q: How is Omniscan administered?

Omniscan is given as an intravenous injection, typically as a rapid bolus or a short infusion immediately before the MRI scan. The exact administration technique and rate are defined by the imaging protocol and the prescribing radiologist.

Q: What are the most serious risks associated with Omniscan?

The most serious risks include nephrogenic systemic fibrosis in patients with severe renal dysfunction and severe hypersensitivity reactions such as anaphylaxis. Prompt recognition and management of these events are essential, and patients with compromised kidney function should be screened before use.

Q: Who should not receive Omniscan?

Omniscan is contraindicated in individuals with an estimated glomerular filtration rate below 30 ml/min/1.73 m², known hypersensitivity to gadodiamide or any component of the formulation, and in patients where alternative imaging without gadolinium is feasible. Clinicians must assess each patient’s suitability before administration.

Gadodiamide, the active ingredient in Omniscan, is a contrast media presented as a 0.5 ml/0.5 mmol injection for intravenous use. It enhances magnetic resonance imaging (MRI) scans, helping radiologists visualize vascular structures and tissue differences in adult and pediatric patients. GNH India supplies Omniscan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and imaging centres worldwide.

GNH India supplies Omniscan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and imaging centres worldwide.

Manufacturer / TM Owner

Ge Healthcare Buchler Gmbh & Co. Kg

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Omniscan is a gadolinium‑based MRI contrast agent used to improve diagnostic imaging of several body systems.

Central nervous system imaging: improves lesion detection and delineation in brain and spinal cord studies.
Cardiovascular imaging: enhances visualization of cardiac chambers, vessels and myocardial perfusion.
Abdominal and pelvic imaging: clarifies lesions in liver, kidneys, pancreas and the reproductive organs.
Angiographic studies: provides high‑contrast definition of arterial and venous structures.
Whole‑body screening: assists in detecting metastatic disease and systemic pathology.

How It Works

Gadodiamide is a gadolinium‑based chelate that distributes in the extracellular fluid after intravenous injection. Its paramagnetic gadolinium ion shortens T1 relaxation times of nearby water protons, producing a brighter signal on T1‑weighted MRI sequences and thereby enhancing the contrast between normal and pathological tissues.

Side Effects

Adverse reactions to Omniscan are generally uncommon but can range from mild to severe.

Common Side Effects

Nausea: transient feeling of stomach upset.
Headache: mild to moderate intensity.
Injection site discomfort: pain or burning at the infusion site.
Warm sensation: brief feeling of heat throughout the body.
Dizziness: temporary light‑headedness.

Serious or Rare Side Effects

Nephrogenic systemic fibrosis (NSF): fibrotic skin changes in patients with severe renal impairment.
Anaphylactoid reaction: sudden onset of hives, swelling, or breathing difficulty.
Severe hypersensitivity: rash, bronchospasm, or hypotension requiring medical intervention.
Cardiac arrest: extremely rare but life‑threatening event.
Renal toxicity: worsening kidney function in susceptible individuals.

Precautions & Warnings

Omniscan should be administered only after evaluating patient history and renal function.

Assess renal function: check eGFR before use, especially in patients with known kidney disease.
Avoid in severe renal impairment: contraindicated when eGFR <30 ml/min/1.73 m².
Monitor for allergic reactions: observe patients during and after injection for signs of hypersensitivity.
Use lowest effective dose: limit gadolinium exposure to the minimum required for diagnostic quality.
Pregnancy and lactation: weigh benefits against potential risks; use only if essential.
Store at ambient temperature: keep below 25 °C, protect from light, and retain in original packaging.

Avoid Interactions

Gadodiamide may interact with other agents that affect renal function or cause hypersensitivity.

Major Interactions (Avoid)

Loop diuretics: can exacerbate renal insufficiency, increasing NSF risk.
High‑dose intravenous iron: may compete for protein binding and alter gadolinium clearance.

Moderate Interactions (Monitor Closely)

Non‑steroidal anti‑inflammatory drugs (NSAIDs): may reduce renal perfusion, requiring closer monitoring of kidney function.
Metformin: assess renal function before use; adjust dosing if significant impairment is detected.
Other gadolinium agents: avoid sequential administration to prevent cumulative gadolinium load.
Radiopharmaceuticals: monitor for additive contrast effects in combined imaging studies.

Frequently Asked Questions

Omniscan is a gadolinium‑based contrast agent used during magnetic resonance imaging (MRI) to improve the visibility of blood vessels, organs and lesions. It helps radiologists obtain clearer images of the brain, heart, abdomen and other body regions, supporting more accurate diagnosis.

Gadodiamide contains a chelated gadolinium ion that is highly paramagnetic. After intravenous injection it distributes in the extracellular fluid and shortens the T1 relaxation time of nearby water protons, producing a brighter signal on T1‑weighted MRI sequences and enhancing the contrast between normal and abnormal tissues.

The dose of Omniscan is determined by the prescribing physician based on the patient’s weight, the imaging protocol and the specific diagnostic requirement. The healthcare professional calculates the appropriate volume and concentration for each individual examination.

Use of Omniscan during pregnancy or lactation should only be considered when the diagnostic benefit outweighs potential risk. Gadolinium agents cross the placenta and may be excreted in breast milk, so clinicians evaluate each case carefully and follow local regulatory guidance.

To order Omniscan, submit an enquiry on the product page at gnhindia.com indicating the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Omniscan is a non‑ionic, linear gadolinium chelate offering high relaxivity and good image enhancement. Compared with macrocyclic agents, it has a similar efficacy for most MRI studies but may carry a slightly higher risk of nephrogenic systemic fibrosis in patients with severe renal impairment, prompting careful patient selection.

Omniscan should be stored at ambient temperature, below 25 °C, protected from light and kept in its original packaging. Do not freeze the product. Before administration, inspect the vial for particulate matter and ensure the solution is clear.

Omniscan is given as an intravenous injection, typically as a rapid bolus or a short infusion immediately before the MRI scan. The exact administration technique and rate are defined by the imaging protocol and the prescribing radiologist.

The most serious risks include nephrogenic systemic fibrosis in patients with severe renal dysfunction and severe hypersensitivity reactions such as anaphylaxis. Prompt recognition and management of these events are essential, and patients with compromised kidney function should be screened before use.

Omniscan is contraindicated in individuals with an estimated glomerular filtration rate below 30 ml/min/1.73 m², known hypersensitivity to gadodiamide or any component of the formulation, and in patients where alternative imaging without gadolinium is feasible. Clinicians must assess each patient’s suitability before administration.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 06 Oct 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.